Items where Author is "Matter-Walstra, Klazien"
Number of items: 9. 2021Sendi, Pedram and Matter-Walstra, Klazien and Schwenkglenks, Matthias. (2021) Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion. Healthcare (Basel, Switzerland), 9 (11). p. 1419. 2018Panje, Cedric M. and Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Gautschi, Oliver and Siano, Marco and Aebersold, Daniel M. and Plasswilm, Ludwig and Lupatsch, Judith E.. (2018) A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 129. pp. 257-263. 2017Gautschi, Oliver and Rothschild, Sacha I. and Li, Qiyu and Matter-Walstra, Klazien and Zippelius, Alfred and Betticher, Daniel C. and Früh, Martin and Stahel, Rolf A. and Cathomas, Richard and Rauch, Daniel and Pless, Miklos and Peters, Solange and Froesch, Patrizia and Zander, Thilo and Schneider, Martina and Biaggi, Christine and Mach, Nicolas and Ochsenbein, Adrian F. and Swiss Group for Clinical Cancer, Research. (2017) Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical Lung Cancer, 18 (3). pp. 303-309. 2014Jakovljevic, Mihajlo and Gutzwiller, Florian S. and Schwenkglenks, Matthias and Milovanovic, Olivera and Rancic, Nemanja and Varjacic, Mirjana and Stojadinovic, Dobrivoje and Dagovic, Aleksandar and Matter-Walstra, Klazien. (2014) Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON, 19 (3). pp. 1111-1120. 2012Matter-Walstra, Klazien and Joerger, Markus and Kühnel, Ursula and Szucs, Thomas and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2012) Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system. Value in health, Vol. 15, H. 1. pp. 65-71. 2011Joerger, Markus and Matter-Walstra, Klazien and Früh, Martin and Kühnel, Ursula and Szucs, Thomas D. and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of oncology, 22 (3). pp. 567-574. 2009Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Pestalozzi, Bernhard C. and Fink, Daniel and Brauchli, Peter and Szucs, Thomas D.. (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer : an economic evaluation. EJC : European journal of cancer, Vol. 45, H. 8. pp. 1397-1406. 2008Matter-Walstra, Klazien and Schoeni-Affolter, Franziska and Widmer, Marcel and Busato, André. (2008) Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine. Journal of Evaluation in Clinical Practice , 14 (1). pp. 75-82. 2006Matter-Walstra, Klazien and Widmer, Marcel and Busato, André. (2006) Analysis of patient flows for orthopedic procedures using small area analysis in Switzerland. BMC Health Services Research, 6. p. 119. |
